Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Greenyn Biotechnology CoROCO:6846 +0.69%68 EV-to-EBIT is 9.10 as of Sep. 09, 2026, which is 11% below its 10-year median of 10.22. GuruFocus rates ROCO:6846 with a GF Score™ of 68/100 and a GF Value™ of NT$67.01 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 365 Biotechnology companies, Greenyn Biotechnology Co ranks better than 60% on this metric.
Greenyn Biotechnology Co (ROCO:6846) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Greenyn Biotechnology Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,835.7 Mil.
Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$177.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenyn Biotechnology Co EV-to-EBIT Related Terms
Greenyn Biotechnology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6846 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Greenyn Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenyn Biotechnology Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Greenyn Biotechnology Co's EV-to-EBIT falls into.
Greenyn Biotechnology Co's current Enterprise Value is NT$1,616.5 Mil.
Greenyn Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$177.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenyn Biotechnology Co (ROCO:6846) has a EV-to-EBIT of 9.10 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Greenyn Biotechnology Co and its competitors. This is 11% below median its historical median of 10.22. Over the past decade, Greenyn Biotechnology Co's EV-to-EBIT has ranged from 7.22 to 15.53. According to the industry distribution chart, Greenyn Biotechnology Co ranks #146 out of 365 companies in the Biotechnology industry, placing it in the top 40%.
Is Greenyn Biotechnology Co's EV-to-EBIT too high?
Greenyn Biotechnology Co's current EV-to-EBIT of 9.10 is 11% below median its 10-year median of 10.22. Over the past 10 years, this metric has ranged from a low of 7.22 to a high of 15.53. The Biotechnology industry median EV-to-EBIT is 15.48. Greenyn Biotechnology Co's value of 9.10 is 41.2% below this industry median. Based on the distribution chart, Greenyn Biotechnology Co ranks #146 out of 365 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Greenyn Biotechnology Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Greenyn Biotechnology Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Greenyn Biotechnology Co ranks #146 out of 365 companies for EV-to-EBIT. This puts Greenyn Biotechnology Co in the upper half of its industry. The industry median EV-to-EBIT is 15.48. Greenyn Biotechnology Co's value of 9.10 is 41.2% below this benchmark. Historically, Greenyn Biotechnology Co's own EV-to-EBIT has ranged from 7.22 to 15.53 over the past decade. While the company's 10-year median is 10.22 vs. the industry median of 15.48, Greenyn Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.48, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenyn Biotechnology Co's current EV-to-EBIT of 9.10 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Greenyn Biotechnology Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenyn Biotechnology Co's current EV-to-EBIT is 9.10, which is 11% below median its own 10-year median of 10.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenyn Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Greenyn Biotechnology Co (ROCO:6846) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$67.01, compared to a current price of NT$58.50 — trading 12.7% below its estimated fair value. The current EV-to-EBIT is 9.10, which is 11% below median its 10-year median of 10.22 and 41.2% below the Biotechnology industry median of 15.48. Greenyn Biotechnology Co's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Greenyn Biotechnology Co (ROCO:6846), the current EV-to-EBIT is 9.10 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Greenyn Biotechnology Co (ROCO:6846) Overvalued in 2026?
Based on GuruFocus' analysis, Greenyn Biotechnology Co stock appears to be undervalued.
The current stock price of NT$58.50 is trading 12.7% below its estimated GF Value™ of NT$67.01.
GuruFocus considers Greenyn Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:6846:
EV-to-EBIT: 9.10 (11% below median its 10-year median of 10.22)
GF Value™: NT$67.01 vs. price of NT$58.50 (12.7% below fair value)
Industry Position: 41.2% below the Biotechnology median (#146 of 365)
No single metric tells the full story. See the ROCO:6846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Greenyn Biotechnology Co Ltd is engaged in the business of health food raw materials production and sales of raw materials and production and sales of formula preparation.
68GF Score
Get the complete analysis for ROCO:6846
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6846 has been successfully added to your 
